STTK Shattuck Labs
- 10.555
- -0.105-0.98%
Shattuck Labs News
Shattuck Labs First Quarter 2024 Earnings: Beats Expectations
Shattuck Labs Inc (STTK) Reports First Quarter 2024 Financial Results
Buy Rating Affirmed for Shattuck Labs Ahead of Key Clinical Trial Updates on SL-172154
HC Wainwright & Co. Reiterates Buy on Shattuck Labs, Maintains $28 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Shattuck Labs (NASDAQ:STTK) with a Buy and maintains $28 price target.
Shattuck Labs: Buy Rating Affirmed on Strong Q1 Financials and Promising Clinical Milestones
Shattuck Labs Cash And Cash Equivalents And Investments Of $114.6M For The Quarter Ended March 31, 2024, Will Be Sufficient To Fund Its Operations Into 2026
Shattuck Labs Cash And Cash Equivalents And Investments Of $114.6M For The Quarter Ended March 31, 2024, Will Be Sufficient To Fund Its Operations Into 2026
Shattuck Labs Q1 2024 GAAP EPS $(0.37) Beats $(0.46) Estimate, Sales $1.115M Beat $228.500K Estimate
Shattuck Labs (NASDAQ:STTK) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.46) by 19.57 percent. This is a 24.49 percent increase over losses of $(0.49
Shattuck Labs 1Q Loss/Shr 37c >STTK
Shattuck Labs 1Q Loss/Shr 37c >STTK
Press Release: Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Le
28% Of This Shattuck Labs Insider's Holdings Were Sold
From what we can see, insiders were net sellers in Shattuck Labs, Inc.'s (NASDAQ:STTK ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it. Althou
Owning 36% Shares,institutional Owners Seem Interested in Shattuck Labs, Inc. (NASDAQ:STTK),
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
Analysts Conflicted on These Healthcare Names: Shattuck Labs (STTK), Johnson & Johnson (JNJ) and Tilray (TLRY)
Shattuck Labs Reports Preclinical Data Demonstrating Therapeutic Utility Of TRIM7 Inhibition To Prevent Or Reverse Acquired Resistance To Immune Checkpoint Therapy
These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1
Needham: Reiterates Shattuck Labs (STTK.US) rating and adjusted from buy to buy rating, target price is $12.00.
Needham: Reiterates Shattuck Labs (STTK.US) rating and adjusted from buy to buy rating, target price is $12.00.
Needham Reiterates Buy on Shattuck Labs, Maintains $12 Price Target
Needham analyst Gil Blum reiterates Shattuck Labs with a Buy and maintains $12 price target.
Strong Buy Rating for Shattuck Labs on Innovative Immunotherapy Pipeline and Leadership
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
AUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p
Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Shattuck Labs (NASDAQ:STTK) has seen its share price rise 227% over the last year, deli
Analysis
Price Target
No Data
